Literature DB >> 31515871

Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.

Thomas Pincez1,2, Josette-Renée Landry1,2,3, Mathieu Roussy1,2,4, Loubna Jouan5, Mélanie Bilodeau1, Louise Laramée1, Françoise Couture6, Daniel Sinnett1,2, Patrick Gendron7, Josée Hébert2,8,9,10, Luc Oligny2,11, Alexandre Rouette5, Thai H Tran1,2, Brian T Wilhelm2,10,12, Henrique Bittencourt1,2, Sonia Cellot1,2,9.   

Abstract

Infant acute lymphoblastic leukemias (ALL) are rare hematological malignancies occurring in children younger than 1 year of age, most frequently associated with KMT2A rearrangements (KMT2A-r). The smaller subset without KMT2A-r, which represents 20% of infant ALL cases, is poorly characterized. Here we report two cases of chemotherapy-sensitive non-KMT2A-r infant ALL. Transcriptome analyses revealed identical ACIN1-NUTM1 gene fusions in both cases, derived from cryptic chromosomal rearrangements undetected by standard cytogenetic approaches. Two isoforms of the gene fusion, joining exons 3 or 4 of ACIN1 to exon 3 of NUTM1, were identified. Both fusion transcripts contained the functional DNA-binding SAP (SAF-A/B, Acinus, and PIAS) domain of ACIN1 and most of NUTM1. The detection of the ACIN1-NUTM1 fusion by RT-PCR allowed the molecular monitoring of minimal residual disease in a clinical setting. Based on publicly available genomic datasets and literature review, we predict that NUTM1 gene fusions are recurrent events in infant ALL. As such, we propose two clinically relevant assays to screen for NUTM1 rearrangements in bone marrow cells, independent of the fusion partner: NUMT1 immunohistochemistry and NUTM1 RNA expression. In sum, our study identifies ACIN1-NUTM1 as a recurrent and possibly cryptic fusion in non-KMT2A-r infant ALL, provides clinical tools to screen for NUTM1-rearranged leukemia and contributes to the refinement of this new subgroup.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  NUTM1; acute lymphoblastic leukemia; gene fusion; infant leukemia; minimal residual disease; transcriptomics

Mesh:

Substances:

Year:  2019        PMID: 31515871     DOI: 10.1002/gcc.22808

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  4 in total

Review 1.  Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.

Authors:  Jianfeng Li; Yuting Dai; Liang Wu; Ming Zhang; Wen Ouyang; Jinyan Huang; Saijuan Chen
Journal:  Front Med       Date:  2021-01-05       Impact factor: 4.592

2.  Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children.

Authors:  Thomas Pincez; Raoul Santiago; Michel Duval; Sonia Cellot; Henrique Bittencourt; Isabelle Louis; Mélanie Bilodeau; Alexandre Rouette; Loubna Jouan; Josette-Renée Landry; Françoise Couture; Johanne Richer; Pierre Teira
Journal:  Bone Marrow Transplant       Date:  2021-09-02       Impact factor: 5.483

Review 3.  NUTM1-Rearranged Neoplasms-A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations-An Updated Review.

Authors:  Wenyi Luo; Todd M Stevens; Phillip Stafford; Markku Miettinen; Zoran Gatalica; Semir Vranic
Journal:  Curr Oncol       Date:  2021-11-07       Impact factor: 3.677

4.  Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia.

Authors:  Eleonora Khabirova; Laura Jardine; Tim H H Coorens; Simone Webb; Taryn D Treger; Justin Engelbert; Tarryn Porter; Elena Prigmore; Grace Collord; Alice Piapi; Sarah A Teichmann; Sarah Inglott; Owen Williams; Olaf Heidenreich; Matthew D Young; Karin Straathof; Simon Bomken; Jack Bartram; Muzlifah Haniffa; Sam Behjati
Journal:  Nat Med       Date:  2022-03-14       Impact factor: 87.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.